Skip to main content

Table 1 Demographics, methotrexate treatment and the phenotype subgroups

From: Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis

 

JIA

JIA patients, n

121

Girls: Boys, n

82:39

Caucasian: not Caucasian, n

117:4

Age at enrolment (years)

13.3 (11.3–15.1)

Duration of MTX treatment (days)

340 (142–766)

MTXo: MTXSC, n

45:76

MTX dose (mg/m2/week)

9.7 (9.0–10.9)

Patients with completed MISS, n

120

MISS total score (0–36)

8 (3–14)

MTXintolerant subgroup1, n

73

MTXtolerant subgroup, n

47

Patients with ≥ 7 completed diary entries, n

77

“MTX-nausea” subgroup2, n

56

  1. Data on demographics, details of the methotrexate (MTX) treatment and the distribution of patients in the phenotype subgroups
  2. Values are expressed as median (IQR) unless otherwise stated. MTXSC; subgroup treated with MTX subcutaneously, MTXo subgroup treated with MTX orally
  3. 1The MTXintolerant subgroup: children with a total score of the Methotrexate Intolerance Severity Score (MISS) ≥6 and at least 1 point in the anticipatory and/or associative and/or behavioral symptoms. Otherwise categorised as MTXtolerant
  4. 2The “MTX-nausea” subgroup: children with a nausea diary illustrating a nausea pattern timely related to the MTX administration